Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality

Danish study (n= 4480) reports no difference in mortality for prior ACEI/ARB use, vs no use after adjustment for confounders. Also, nested case-control analysis (n= 494,170) found use of ACEI/ARB, vs other antihypertensives, was not associated with higher incidence of COVID-19.

SPS commentary:

A related editorial notes that the findings of this study, and that of previous studies in other patient populations, should lay to rest concerns about the use of ACEI/ARBs in patients with or at risk for COVID-19.

 

They add that where there is a clinical indication for their use, ACEI/ARBs should not be discontinued in patients with COVID-19, unless the drugs cannot be tolerated due to haemodynamic instability.

Journal of the American Medical Association

Resource links:

Editorial